Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis

Present evidence is insufficient to recommend GLP-1 RAs as standard RA therapy. Well designed randomized controlled trials are needed to establish their efficacy and optimal role.

Authors

Institutions

Publication Details

Journal
Current Opinion in Rheumatology
Published
2026-03-04
DOI
https://doi.org/10.1097/bor.0000000000001153
Primary Topic
Diabetes Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis

Angela G. Malani, Aaron Stubbs, Ryan Massay
Current Opinion in Rheumatology
Diabetes Treatment and Management
article

Glucagon-like peptide-1 receptor agonists in rheumatoid arthritis

Angela G. Malani, Aaron Stubbs, Ryan Massay
article en

Abstract

Present evidence is insufficient to recommend GLP-1 RAs as standard RA therapy. Well designed randomized controlled trials are needed to establish their efficacy and optimal role.

Current Opinion in Rheumatology
University of Michigan (US)
Good health and well-being
Openalex Percentile: Top 34%
Diabetes Treatment and Management
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.